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Background: Immunophenotypic analysis of the bone marrow (BM) cells has proven to be helpful in the diagnosis
of Myelodysplastic Syndromes (MDS). However, the usefulness of flow cytometry (FCM) for the detection of
myelodysplasia in the peripheral blood (PB) still needs to be investigated. The aim of this pilot study was to
evaluate the value of FCM-based PB neutrophil and monocyte immunophenotyping for the diagnosis of lower
risk MDS (LR-MDS).
Methods: We evaluated by 8-color FCM the expression of multiple cell surface molecules (CD10, CD11b, CD11c,
CD13, CD14, CD15, CD16, CD34, CD45, CD56, CD64 and HLA-DR) in PB neutrophils and monocytes from a series
of 14 adult LR-MDS patients versus 14 normal individuals.
Results: Peripheral blood neutrophils from patients with LR-MDS frequently had low forward scatter (FSC) and
side scatter (SSC) values and low levels of CD11b, CD11c, CD10, CD16, CD13 and CD45 expression, in that order,
as compared to normal neutrophils. In addition, patients with LR-MDS commonly display a higher fraction of
CD14+CD56+ and a lower fraction of CD14+CD16+ monocytes in the PB. Based on these results, we proposed an
immunophenotyping score based on which PB samples from patients with LR-MDS could be distinguished from
normal PB samples with a sensitivity 93% and a specificity of 100%. In addition, we used this score to construct
the MDS Thermometer, a screening tool for detection and monitoring of MDS in the PB in clinical practice.
Conclusions: Peripheral blood neutrophil and monocyte immunophenotyping provide useful information for
the diagnosis of LR-MDS, as a complement to cytomorphology. If validated by subsequent studies in larger
series of MDS patients and extended to non-MDS patients with cytopenias, our findings may improve the
diagnostic assessment and avoid invasive procedures in selected groups of MDS patients.
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Myelodysplastic Syndromes (MDS) are a group of myeloid
neoplasms characterized by inefficient hematopoiesis, per-
ipheral blood (PB) cytopenias and high risk of leukemic pro-
gression [1–3]. According to World Health Organization
(WHO) classification, lastly updated in 2016, the diagnosis
is essentially based on morphological and cytogenetic ab-
normalities, such as the presence of cytopenias, blasts in
the PB and/or bone marrow (BM), and dysplasia in one or
more hematopoietic cell lineages [4, 5]. Although PB cyto-
morphological findings provide information to suspect of
MDS, only BM studies are presently accepted to confirm
the diagnosis [4, 5].
Five major MDS subtypes are currently recognized
(WHO, 2016): MDS with single lineage dysplasia (MDS-
SLD), MDS with multilineage dysplasia (MDS-MLD),
MDS with ring sideroblasts (MDS-RS), MDS with iso-
lated deletion of chromosome 5q [MDS-del(5q)], MDS
with excess of blasts (MDS-EB), and MDS, unclassifiable
(MDS-U) [5]. The International Prognostic Scoring Sys-
tem (IPSS), has been used to estimate risk for progres-
sion to acute myeloid leukemia (AML) or death from
cytopenia-related complications. [6]. Patients categorized
as low or intermediate-1 risk using the IPSS are usually
referred to as “lower-risk” MDS (LR-MDS), whereas
those classified as intermediate-2 or high risk are usually
termed “higher-risk” MDS (LR-MDS). In its revised ver-
sion, the IPSS incorporated new BM blast classes and
cytogenetic abnormalities, and included both number
and severity of cytopenias, thereby defining five (very
low, low, intermediate, high and very high) risk categor-
ies, from which the first three correspond to LR-MDS
[7]. In general, these include MDS-SLD, MDS-MLD,
MDS-RS and MDS-del(5q).
Most of the LR-MDS patients, who account for around
60% of newly diagnosed MDS cases, remain simply on
supportive care, being dependent on red blood cell
(RBC) and/or platelet transfusions, and/or receiving
hematopoietic growth factors; about 1/3 of the patients
only require monitoring (“wait and see”) [8]. HR-MDS
patients may benefit from intensive treatments, although
most of them are not eligible due to increased age and/
or comorbidities, thereby being selected for low-
intensity treatment regimens [8].
Flow cytometry (FCM) is a highly sensitive technique
for evaluation of the hematopoietic cells. It has been
used with increasing frequency to study the BM from
patients with MDS, being considered a promising tool to
improve MDS diagnosis, especially in cases of minimal
dysplasia, absence of cytogenetic abnormalities, and BM
hypocellularity or fibrosis [9–16]. Its value in the diagno-
sis of Chronic Myelomonocytic Leukemia (CMML) and
other Myelodysplastic/myeloproliferative neoplasms
(MDS/MPN) has also been documented [17–20].Flow cytometry has an increasing importance in MDS
diagnosis and subtyping, and in predicting the clinical
outcome [15, 21]. However, a systematic histological
and immuno-histochemical examination of the BM is
still required for the final diagnosis and classification of
MDS [22].
Several immunophenotypic abnormalities have been
reported by FCM in the BM from MDS patients. Some
examples are increased numbers of CD34+ precursors,
abnormal expression of cell surface molecules on myelo-
blasts, maturing granulocytic and monocytic cells, or
erythroid precursors, and lineage infidelity [13]. For in-
stance, phenotypic abnormalities of CD34+ cells and
their compartments have been reported in MDS, with
LR-MDS patients typically having an expansion of mye-
loid CD34+ cells at the expense of lymphoid B-cell
precursors, while expansion of immature CD34+ cells
occurs in HR-MDS [11, 23]. Aberrant antigen expression
(e.g., CD5, CD7 and CD56), and over or under expres-
sion of other cell surface markers (e.g. CD13, CD34,
CD45, CD117 and HLA-DR) on CD34+ myeloblasts
have also been reported [12, 24].
Asynchronous shift to the left in maturing granulocytes
is also frequent in the BM from patients with MDS, with
neutrophil-precursors and maturing neutrophils having
decreased size and granularity, and, consequently, a lower
light scatter. Abnormal/Asynchronous expression of
CD11b, CD13, CD15 and CD16 molecules has also been
described, reflecting an anomalous neutrophil maturation
[9, 10, 12]. Likewise, BM monocytes from MDS patients
frequently have abnormal maturation patterns, as evalu-
ated by the expression of CD14, CD34, CD36, CD64, and
HLA-DR. Erythroid dysplasia has also been documented
by FCM, by studying a set of molecules that are expressed
differently throughout the maturation of RBC in the BM,
such as CD35, CD36, CD44, CD45, CD71, CD105, CD117
and CD235a [9, 12, 25, 26].
Even though the collection of a PB sample is much
simpler and much less invasive than a BM aspirate
and/or biopsy, nearly all FCM studies in MDS patients
have been performed in BM samples; the immunophe-
notypic alterations in PB cells have been much less ex-
plored [27–31].
Taking in consideration the accessibility of PB samples,
it would be useful to establish FCM criteria for the diag-
nosis of myelodysplasia in the PB, especially in patients
with LR-MDS. Therefore, the purpose of this study was
to search the presence of abnormal and/or aberrant anti-
gen expression in circulating neutrophils and monocytes
from these patients. Based on the results obtained, a
straightforward FCM-based scoring system is proposed,
which allows to distinguish PB samples of patients with
LR-MDS from normal PB samples with a high sensitivity
and specificity. Using this scoring schema we, conceived
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tection and monitoring of MDS in the PB in clinical
practice.
Methods
Study population and design
This study included 14 patients with LR-MDS, 8 males
and 6 females, with a median age of 76 years, ranging
from 66 to 88 years, that had been followed in the
Hematology Department of Centro Hospitalar do Porto,
Porto, Portugal, and that had at least one appointment
at the hospital from September 2015 to November 2015.
An equal number of healthy controls (blood donors)
were studied in parallel, 8 males and 6 females, with a
median age of 55 years, ranging 19 to 63 years. First
time donors, and donors with a history of infection in
the previous 3 months and/or who have had neoplasms
were excluded.
Clinical and laboratory data were retrospectively col-
lected from the hospital records. Patients were consid-
ered to have anemia, neutropenia and thrombocytopenia
if hemoglobin (Hg) < 12.5 g/dL, neutrophils < 2.000 × 106/L
and platelets < 150 × 109/L, respectively.
The diagnosis and classification of MDS were estab-
lished according to the WHO criteria, revised in 2016
[4, 5], after excluding other conditions that could poten-
tially contribute to BM dysplasia and/or cytopenias.
Only the following LR-MDS categories were included:
MDS-SLD, MDS-MLD, MDS-RS and MDS-del(5q).
In order to avoid artefactual effects on neutrophil and
monocyte immunophenotypes, patients who were being
treated with granulocyte (G-CSF) or granulocyte-
macrophage (GM-CSF) colony stimulating factors (CSF)
at the time of the study or in the preceding 3 months
were excluded, as did patients submitted to cytoreductive
therapy, lenalidomide, hypomethylating and/or immuno-
suppressive treatments, and patients with concomitant
infections or other neoplastic diseases. Previous or con-
comitant treatments with erythropoietin (EPO) and
thrombopoietin receptor agonists were not exclusion cri-
teria, neither did iron chelating therapies, vitamins or
other nutrients.
The IPSS and the revised IPSS (IPSS-R) were calcu-
lated for all patients with MDS as previously described
[6, 7]. Levels of Hg < 10.0 g/dL, neutrophils < 1800 × 106/L
and platelets < 100 × 109/L were considered for risk stratifi-
cation. The IPSS criteria were used to derive the karyotype-
based risk classification [6].
Transfusion-related variables included the cumulative
transfusion burden (total number of RBC units) and
transfusion intensity (median number of RBC units/
month). Transfusion-dependency was defined according
to the WHO classification-based Prognostic Scoring Sys-
tem criteria [2].Given the fact that elevated lactate dehydrogenase
(LDH) has been associated with decreased overall
survival [32], serum LDH levels were also evaluated.
Moreover, as most patients with MDS were RBC
transfusion-dependent [14, 33], and iron overload has
been associated with worse prognosis in patients with
LR-MDS [34], the serum ferritin levels were measured.
Bone marrow aspirate samples were used to prepare
BM smears. These were stained with Leishman’s stain,
and cell morphology was analyzed by conventional light
microscopy. In each case, a Perls’ Prussian blue stain
was performed. Other special stains were used whenever
considered helpful. The acceptable quality of samples
was defined according to the guidelines of the Inter-
national Council for Standardization in Hematology
[35]. Erythroid and granulocytic dysplasia were defined
by the presence of ≥10% BM cells of the respective
lineage with morphological alterations; presence of ≥15%
ringed sideroblasts was also considered a diagnostic cri-
teria for erythroid dysplasia. Megakaryocytic dysplasia
was recognized by the presence of morphological abnor-
malities. Morphological features used for the definition
of myeloblasts were those proposed by the International
Working Group on Morphology of MDS [35], and the
blast cell percentage was determined using the overall
number of BM nucleated cells as denominator.
Bone marrow biopsy specimens were fixed in neutral-
buffered formalin or Bouin’s fixative solution, decalcified,
and embedded in paraffin-wax. Standard routine stains
included hematoxylin & eosin and/or Giemsa, and
Gömöri’s silver stain for the evaluation of BM fibrosis
[36]. Immunohistochemistry was done in specific cases.
The BM cellularity was estimated based on the age-
adapted normal values [36], and dysmyelopoiesis was
evaluated as previously described [37, 38].
Cytogenetics studies were performed in BM aspirates,
either by conventional cytogenetics and/or fluorescence
in situ hybridization (FISH). Conventional cytogenetics
was performed on direct and 24- to 48-h unstimulated
BM cultures, analyzed following trypsin Giemsa banding;
20 metaphases were evaluated. In FISH studies, VYSIS
DNA FISH probes (Abbott Molecular Inc., IL, USA)
were used to detect numeric and structural abnormal-
ities on chromosomes 5, 7 and 20, and numeric abnor-
malities on chromosomes 8 and X. Two hundred
interphase nuclei were counted. Cytogenetic classifica-
tion was performed by grouping patients according to
Schanz et al. [39].Flow cytometry studies
Peripheral blood samples were collected into ethylene-
diamine-tetra-acetic acid tripotassium salt containing
tubes and processed within 24 h after collection.
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FCM using fluorochrome conjugated monoclonal anti-
bodies (mAbs) with different specificities (Table 1).
These mAbs were combined in two different tubes, con-
ceived to quantify immature CD34+ cell in the PB and to
evaluate cell surface antigen expression in circulating
neutrophils (mostly tube 1) and monocytes (mostly tube
2) (Table 2). A normal PB sample was run in parallel
with each patient PB sample.
Cell staining was done using a whole blood stain-lyse-
and-then-wash method, and the BD FACS™ Lysing Solu-
tion, according to the instructions of the manufacturer.
Sample acquisition was performed in a BD FACSCanto
II™ flow cytometer. Forward scatter (FSC) and side
scatter (SSC) were captured on a linear scale, and SSC
was represented with a mathematical transformation
(Exp-SSC-Low). For fluorescence parameters, a logarith-
mic amplification was used, with logical transformation.
At least 200,000 cell events per tube were recorded and
stored as flow cytometry standard (.fcs) 3.0 files.
Flow cytometer set-up and calibration was performed
accordingly to the Euroflow consortium Standard Oper-
ating Procedures [40], available in [41]. Daily control
was monitored by plotting fluorescence intensity values
in Levy Jennings charts. External quality assessment/pro-
ficiency testing was performed by participating in the
Euroflow Quality Assurance program [42].
Flow cytometry data analysis was done using the Infi-
nicyt™ software (Cytognos, Salamanca, Spain). Neutro-
phils, monocytes and blast cells were identified and
classified according to their SSC and FSC characteristics
and antigen expression profiles, as described in Fig. 1.Table 1 Specificities, clones, isotypes, fluorochromes and
manufacturers of the monoclonal antibodies used in this study
Antigen Clone Isotype Fluorochrome Manufacturer
CD10 ALB1 IgG2a PE-Cy7 BC-IOT
CD11b D12 IgG2a APC BDB
CD11c S-HCL-3 IgG2b APC BDB
CD13 L138 IgG1 PE BDB
CD14 HCD14 IgG1 APC-H7 BL
CD15 MMA IgM FITC BDB
CD16 3G8 IgG1 V450 BDH
CD34 8G12 IgG1 PerCP-Cy5.5 BDB
CD45 J.33 IgG1 KO BC-IOT
CD56 N901-HLDA6 IgG1 PE-Cy7 BC-IOT
CD64 22 IgG1 PE BC-IOT
HLA-DR L243 IgG2a FITC BDB
Abbreviations: APC allophycocyanin, Cy5.5 Cyanine 5.5, Cy7 Cyanine 7, FITC
Fluorescein, isothiocyanate, KO Khrome Orange, PE Phycoerythrin, PerCP
Peridinin chlorophyll protein, V450 Violet 450, BC Beckman Coulter, BDB
Becton Dickinson Bioscience, BDH Becton Dickinson Horizon, BL Biolegend,
IOT ImmunotechMonocytes were further subdivided into classical (CD14
+highCD16−), intermediate (CD14+highCD16+) and proin-
flammatory (CD14+lowCD16+) monocytes. Non-classical
(CD14+CD16+, intermediate + proinflammatory) mono-
cyte subsets were considered together in succeeding
analysis. Neutrophils and monocytes were analyzed for
the levels of expression of CD10, CD11b, CD11c, CD13,
CD15, CD16, CD56, CD64, and HLA-DR, by recording
the median fluorescence intensity (MedFI) for each
marker. The relative representation of CD14+CD16− and
CD14+CD16+ monocyte subsets and the percentage of
CD56+ monocytes were also recorded.
The FSC/SSC values and MedFI values obtained in
neutrophils and monocytes from patients with LR-MDS
were considered abnormal when they were out of the
mean value ±2 standard deviations (SD) of the same
parameter obtained in PB neutrophils and monocytes
from healthy individuals.
Immunophenotypic scores for myelodysplasia
Neutrophil scores
Two different scoring schemas were used for neutrophils.
The scoring schema type 1 was based only on the number
of abnormally low parameters found in PB neutrophils
(below the mean-2SD of the values found for the same
parameter in normal PB neutrophils). The scoring schema
type 2 took into account both the number of abnormally
low parameters and the severity of each parameter defi-
ciency, as previously described [11, 23].
In both cases, values within the mean ± 2SD or above
the mean + 2SD were scored with “0”, and in both cases
only 8 of the parameters analyzed (FSC, SSC, CD10,
CD11b, CD11c, CD13, CD16 and CD45) were consid-
ered for scoring. The neutrophil score, ranging from 0
to 8 in both cases, was calculated for each patient by
adding up the scores obtained for each of the 8 parame-
ters evaluated. Three groups corresponding to an overall
score of “0”, 1 and ≥2 were arbitrarily considered equiva-
lent to “no neutrophil dysplasia”, “possible neutrophil
dysplasia” and “neutrophil dysplasia”, respectively. Cases
with a neutrophil score ≥ 2 were subsequently arbitrarily
classified as having mild (scores 2 and 3), moderate
(scores 4, 5 and 6) and severe (scores 7 and 8) neutro-
phil dysplasia, respectively.
Neutrophil scoring schema 1 Each abnormally low
parameter (below the mean-2SD) was scored with 1
point.
Neutrophil scoring schema 2 Values of 0.25, 0.5 or 1.0
were given when the MedFI value obtained for each of
the phenotypic variables evaluated were between the
mean-2SD and the mean-3SD, between the mean-3SD
and the mean-4 SD, or below the mean-4SD of the
Table 2 Eight color-combinations of the fluorochrome-conjugated monoclonal antibodies used in this study
Tubes FITC PE PerCP-Cy5 PE-Cy7 APC APC-H7 V450 KO
1 CD15 CD13 CD34 CD10 CD11b CD14 CD16 CD45
2 HLA-DR CD64 CD34 CD56 CD11c CD14 CD16 CD45
Abbreviations: APC allophycocyanin, Cy5.5 Cyanine 5.5, Cy7 Cyanine 7, FITC Fluorescein, isothiocyanate, KO Khrome Orange, PE Phycoerythrin, PerCP Peridinin
chlorophyll protein, V450 Violet 450
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trophils, respectively.Monocyte scores
For monocytes, only the percentages of CD14+CD56+
and CD14+CD16+ monocytes on total monocytes were
used to calculate the FCM monocyte score for myelo-
dysplasia. Aberrant high CD56 expression was defined
as a percentage of CD56+ cells exceeding the mean +
2SD of the values found in normal PB monocytes. Ab-
normal low CD16 expression was defined as a percent-
age of CD14+CD16+ monocytes of less than 5% of total
monocytes. Depletion of non-classical monocytes was
arbitrarily considered mild, moderate or severe when
CD14+CD16+ cells accounted for less than 5%, 2.5% and
1.25% of total monocytes, respectively. The overall
monocyte score, ranging from 0 to 2, was calculated forFig. 1 Bivariate dot-plots obtained from a normal PB sample, illustrating th
quantification and characterization of neutrophils, monocytes, and CD34+ c
61.16%) were selected based on their SSC/FSC characteristics and CD45+low
based on SSC/FSC and CD45+intCD14+ expression; subsequently, monocyte
classical (either intermediate CD14+highCD16+ or proinflammatory CD14+low
cells (black dots, 0.02%) were identified based on SSC/FSC and CD45+lowCD
granulocytes, including promyelocytes, myelocytes and metamyelocytes (p
Abbreviations: FSC, forward scatter; PB, peripheral blood; SSC, side scattereach patient by adding up the scores obtained for each
of the 2 parameters evaluated.
As described for neutrophils, two different scoring
schemas were used for monocytes: scoring schema type
1, based only on the number abnormal parameters
found in PB monocytes, and scoring schema type 2,
taking into account both the number of abnormal pa-
rameters and the severity of each parameter abnormal-
ity. The monocyte score, ranging from 0 to 2, was
calculated for each patient by adding up the scores
obtained for each of the 2 parameters evaluated. Three
groups corresponding to an overall score of 0, 1 and 2,
were arbitrarily considered equivalent to “no monocyte
dysplasia”, “possible monocyte dysplasia” and “mono-
cyte dysplasia”, respectively.
Monocyte scoring schema 1 Each abnormal parameter
(percentage of CD56+ cells exceeding the mean + 2SDe analysis procedure used for the immunophenotypic identification,
ells, after excluding cell debris and doublets. Neutrophils (red dots;
CD16+high expression. Monocytes (blue dots; 7.64%) were selected
s were separated into classical (light blue dots; 6.88%) and non-
CD16+, dark blue dots; 0.76%) monocyte subsets. Immature CD34+
34+ expression. Other cells: eosinophils (pink dots; 4.93%); immature
urple dots; 0.27%); lymphocytes and basophils (gray dots; 25.97%).
Table 3 MDS categories and risk stratification of the patients
included in this study
Diagnosis (WHO 2016)a
MDS-RS 6/14 (43%)
MDS-SLD 4/14 (29%)
MDS-MLD 3/14 (21%)
MDS-del(5q) 1/14 (7%)
International Prognostic Scoring System (IPSS)
IPSS score 0.3 ± 0.4; 0 (0–1.0)
Score = 0.0 8/14 (57%)
Score = 0.5 3/14 (21%)
Score = 1.0 3/14 (21%)
Score > 1.0 0/14 (0%)
IPSS risk groups
Low risk 8/14 (57%)
Intermediate risk 1 6/14 (43%)
Intermediate risk 2 0/14 (0%)
High risk 0/14 (0%)
Cytogenetic based risk classificationb
Very good 0/10 (0%)
Good 9/10 (90%)
Intermediate 1/10 (10%)
Poor 0/10 (0%)
Very poor 0/10 (0%)
Abbreviations: IPSS International Prognostic Scoring System, MDS
myelodysplastic syndromes, MDS-del(5q) MDS with isolated deletion of
chromosome 5q, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS
with ring sideroblasts, MDS-SLD MDS with single lineage dysplasia, WHO World
Health Organization
Results are expressed as absolute and (relative) frequencies
a Patients with MDS unclassifiable or with ≥20% blast in the BM were omitted,
as did patients with MDS with excess of blasts, and patients diagnosed with
Myelodysplastic/myeloproliferative neoplasms
b Cytogenetic scoring: Very good: -Y, del(11q); Good: normal, del(5q), del(12p),
del(20q), double including del(5q); Intermediate: del(7q), + 8, + 19, i(17q), any
other single or double independent clones; Poor: −7, inv.(3)/t(3q), del3q,
double including − 7/del(7q), complex (3 abnormalities); Very poor: complex
(> 3 abnormalities)
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point.
Monocyte scoring system 2 Values of 0.25, 0.5 or 1
were given when the % of CD56+ monocytes were be-
tween the mean + 2SD and the mean + 3SD, between the
mean + 3SD and the mean + 4 SD, or above the mean +
4SD of the values found for the same parameter among
normal PB monocytes, respectively. Values of 0.25, 0.5
or 1 were assumed when the percentages of CD16+
monocytes were between the 2.5 and 5.0%, between
1.25% and 2.5% and below 1.25%, respectively.
Myeloid immunophenotypic scores
Two myeloid immunophenotypic MDS scores, type 1
and type 2, both ranging from 0 to 10, were obtained
for each patient by adding up the correspondent neu-
trophil and monocytic MDS scores. Three groups cor-
responding to overall scores of “0”, 1 and ≥2 were
arbitrarily considered equivalent to “no myelodyspla-
sia”, “possible myelodysplasia” and “myelodysplasia”,
respectively. Cases with a myeloid score ≥ 2 were sub-
sequently classified as having mild (scores 2 to 4),
moderate (scores 5 to 7) and severe (scores 8 to 10)
myelodysplasia, respectively.
MDS thermometer
The MDS Thermometer was conceived as a screening
tool for detection and monitoring of MDS in clinical
practice. It consists in a visual analogue scale rated
from 0 to 10 points (myeloid thermometer) with two
domains (neutrophil thermometer, rated from 0 to 8,
and monocyte thermometer, rated from 0 to 2) based
on the immunophenotypic scores defined above. For
simplicity, only the neutrophil and monocyte scoring
schemas type 1 were used to construct the MDS
Thermometer presented in this paper. The concept was
based on the Emotion Thermometers Tool, created by
Alex J Mitchell [43, 44].
Statistical analysis
Results were expressed as absolute and relative frequen-
cies, or as mean, median, SD, minimum and maximum
values. Results obtained in PB samples of MDS patients
were compared with those obtained in control PB sam-
ples. The non-parametric Mann-Whitney U test was
used to compare the MedFI observed for each marker in
PB neutrophils and monocytes from MDS patients and
controls, as well as to compare blood cell counts at the
time of the study with those at diagnosis. P values < 0.05
were considered statistically significant. All statistical
analyses were performed using the SOFA Statistics ver-
sion 1.4.5 (Paton-Simpson & Associates Ltd., Auckland,
New Zealand).Results
Study population
Table 3 summarizes the demographic, clinical and la-
boratory data of the study population. Detailed data can
be found in Supplementary Material (Additional file 1:
Table S1).
According to the WHO criteria, 6 patients were classi-
fied as MDS-RS, 4 patients had MDS-SLD, 3 patients
had MDS-MLD, and 1 patient was classified as MDS-
isolated 5q- (Table 3).
Using the IPSS, all patients were categorized as LR-
MDS: 8 patients had low IPSS risk and 6 patients had
intermediate 1 IPSS risk (Table 3).
Cytogenetic based stratification revealed good or inter-
mediate risk in 9 cases and 1 case, respectively (Table 3).
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testing for − 5/5q-, − 7/7q-, + 8, and 20q-, identified in
cytogenetic aberrancies in only 2 out 10 cases (20%),
corresponding to isolated del(5q) (1 patient) and isolated
monosomy 8 (1 case); cytogenetic data were unavailable
in 4 cases (Additional file 1: Table S1).
The median time from the diagnosis was 7.6 years,
ranging from 0.5 to 12.6 years.
At diagnosis, all the MDS patients had anemia, but
only 5 (36%) had neutropenia and only 4 (29%) had
thrombocytopenia (Additional file 1: Table S1). The median
values of the Hg levels, and neutrophil and platelet counts
were of 9.1 g/dl, 2567 × 106/L, and 200 × 109/L ranging
from 7.2 to 11.9, 575 to 7025 and 61 to 591, respectively.
Abnormal RBC morphology in the PB smears were present
in all cases, whereas abnormal neutrophil and/or platelet
morphological features were observed in 4 patients (29%)
each. At the time of the study, the Hg levels were signifi-
cantly lower than those observed at the diagnosis (p =
0.006), despite of RBC transfusions; no statistically signifi-
cant differences were found for the neutrophil and platelet
counts, neither for the percentage of blasts in the PB (p >
0.05). In addition, although a higher fraction of patients had
neutropenia and/or thrombocytopenia, as compared to that
observed at diagnosis, differences were also not statistically
significant (p > 0.05) (Additional file 1: Table S1 footnote).
Most patients had received RBC transfusions, and
most of them had been treated with hematopoietic
growth factors at some point during the course of the
disease (Additional file 1: Table S1). Concerning blood
transfusions, 13 patients (93%) had received at least one
RBC unit, and eleven (79%) had been regularly trans-
fused (transfusion-dependent). The median number of
RBC units received per transfused patient was of 57,
ranging from 15 to 462, and a median number of RBC
transfused per patient/month was of 1.4, ranging from
0.3 to 4.0 (Additional file 1: Table S1). The mean ferritin
serum levels were of 1854 ± 1126 ng/ml, with 93% of the
patients showing increased serum ferritin values, com-
patible with iron overload. None of the patients was re-
ceiving iron-chelating therapies. In addition, none was
medicated with myeloid growth factors (exclusion cri-
teria), although 5 patients had been treated with G-CSF
in the past. Only 2 patients were being treated with EPO
at the time of the study, although most of them had
previously received EPO. No patients had ever received
GM-CSF or thrombopoietin receptor agonists. Increased
serum LDH levels were seen in only 3 cases (23%), at
the time of the study (Additional file 1: Table S1).
Flow cytometry studies
Peripheral blood neutrophils
Neutrophils from patients with LR-MDS had lower FSC
and SSC values as compared with controls (p = 0.008and p < 0.001, respectively) (Figs. 2 and 3, and
Additional file 2: Table S2).
In addition, neutrophils from patients with LR-MDS
had significantly decreased expression of CD10 (p <
0.001), CD11b (p < 0.001), CD11c (p < 0.001), CD13 (p =
0.022) and CD16 (p = 0.002) when compared to normal
individuals. No statistically significant differences were
observed for CD15 and CD45 expression (p > 0.05),
although both markers had a slight reduction in fluores-
cence intensity in patients, as compared to controls.
When analyzed individually, neutrophils from most
LR-MDS patients had abnormally low FSC and/or SSC
(71% and 57% of cases, respectively) (Table 4). Among
the cell surface molecules evaluated, CD11b, CD11c,
CD10, CD16, CD13 and CD45 were the most frequently
affected, in that order; the percentage of cases showing
reduced levels of expression of these molecules were of
71%, 71%, 64%, 43%, 29% and 14%, respectively (Table 4).
Overall, 13 patients (93%) had abnormally low expres-
sion of 2 or more (out of 9) molecules on neutrophils,
with 7 patients (50%) having abnormally low expression
of 5 or more parameters. In addition, 4 cases had abnor-
mally high expression of CD10, CD11b, CD13 or CD45
on circulating neutrophils (1 case each).
In contrast, abnormal levels of cell surface molecules
were found in only 4 controls, and the phenotypic
abnormalities were restricted to one parameter in all
cases (abnormally high CD11b levels: n = 1; abnormally
high CD15 levels: n = 1; abnormally low CD15 levels:
n = 1; abnormally low CD45 levels: n = 1).
The only patient with a normal neutrophil immuno-
phenotype was a 75 year-old female classified as having
MDS-SLD, who had mild macrocytic anemia (Hg 9.0 g/dL,
MCV 104.1 fL) and mild thrombocytopenia (platelet
count of 100 × 106/L). The BM was hypocellular, with
5.3% blast cells, increased myeloid/erythroid ratio
(3.9) and mild dyserythropoiesis, with normal myeloid
and megakaryocytic lineages. BM cytogenetics have
revealed a 46,XX karyotype with 3 metaphases with
non-clonal aneuploidies. The time from the diagnosis
was of 31 months, the patient had been occasionally
transfused (total of 3 RBC units), and the cytopenias
have remained stable over time.
When the healthy controls were separated in two
groups according to age (< 55 years old, n = 7 versus ≥
55 years old, n = 7), we did not observe statistically sig-
nificant differences for any of the parameters analyzed
on neutrophils; also, no differences were found between
males and females (p > 0.05 in all cases).
Peripheral blood monocytes
In general, monocytes from patients with LR-MDS had
light scatter properties similar to the monocytes from
normal individuals (p > 0.05) (Fig. 4 and Additional file 3:
Fig. 2 FSC, SSC and surface antigen expression in PB neutrophils from patients with LR-MDS and healthy individuals (controls). Results as expressed
as arbitrary units of fluorescence intensity. Lower whiskers are 1.5 times the Inter-Quartile Range below the lower quartile, or the minimum value,
whichever is closest to the middle. Upper whiskers are calculated using the same approach. Outliers are displayed. Abbreviations: FSC, forward scatter;
LR-MDS, lower risk myelodysplastic syndromes; MFI, median fluorescence intensity; PB, peripheral blood; SSC, side scatter
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CD14, CD15, CD45 and CD64 expression on monocytes
did not differ significantly from those observed in con-
trols (p > 0.05). However, monocytes from patients with
LR-MDS had significantly higher levels of CD56 (p =
0.006), and lower levels of CD11c (p = 0.004), CD16 (p =
0.005) and HLA-DR (p = 0.042), and showed a tendency
for a lower CD11b expression (p = 0.089), as compared
to controls.
Despite of the above-mentioned differences between
monocytes from LR-MDS patients and controls, the in-
dividual analysis of the analyzed cell surface markers on
monocytes was much less informative than that found inneutrophils, with an abnormal monocyte immunopheno-
type being found in only a limited number of cases.
One of the most consistent aberrancies found in MDS
monocytes consisted in abnormally high levels of CD56
expression, observed in 6 cases (43%), with increased
percentages of CD56+ monocytes. In accordance, mono-
cytes from LR-MDS patients had significantly higher
percentages of CD56+ cells, as compared to normal indi-
viduals (median values of 15% and 7%, ranging from 0 to
99% and from 0 to 15%, respectively; p = 0.026) (Fig. 5
and Table 5). Increased percentages of CD14+CD56+
monocytes (> 18%) were found in 6 (43%) MDS patients
but in none of the healthy individuals, and in most of
Fig. 3 Bivariate SSC/FSC, SSC/CD10, SSC/CD11b, SSC/CD11c, SSC/CD13, SSC/CD15, SSC/CD16 and SSC/CD45 dot plots illustrating the decreased
FSC/SSC and the diminished expression of cell surface molecules (CD10, CD11b, CD13 and CD16) in the PB neutrophils (red dots) from one
patient with LR-MDS, as compared to a healthy individual (control). Red dots, neutrophils; light gray dots, lymphocytes and eosinophils; dark gray
dots, monocytes. Abbreviations: FSC, forward scatter; LR-MDS, lower risk myelodysplastic syndromes; PB, peripheral blood; SSC, side scatter
Aires et al. BMC Hematology  (2018) 18:6 Page 9 of 20the patients (4, 29%), CD14+CD56+ monocytes were
markedly increased (> 28%). CD56 expression was mainly
observed on classical CD14+highCD16− monocytes (Fig. 5,
panel B).
Another recurrent aberrancy observed in LR-MDS
patients consisted in a marked decrease in the fraction
of CD14+CD16+ monocytes, comparatively to controls
(median values of 3% and 12%, ranging from 0 to 8%
and from 4 to 28%, in patients and in controls, respect-
ively; p < 0.001) (Fig. 5 and Table 5). In overall, 9 patients
(64%) had decreased percentages of CD14+CD16+
monocytes (< 5%), when compared to only 2 (14%) of
the controls. Curiously, the severity of the deficiency
was higher in patients than in controls, with 50% of the
patients, but none of the controls, having a moderate
(< 2.5%) or severe (< 1.25%) deficiencies of CD14+CD16+
monocytes.
Finally, abnormally low CD11b and HLA-DR expres-
sion was found in 5 (36%) and 4 (28%) patients, respect-
ively. Less frequent findings included abnormally low
levels of CD45 (2 patients, 14%), and decreased CD11cand CD64 expression (1 case each, 7%); moreover, ab-
normally high levels of CD14 and CD64 were found in 2
cases each, and abnormally high levels of CD11b in only
1 case; cases with abnormal CD13 expression were not
found.
When the healthy volunteers aged 55 years or over
were compared to those who were younger than 55 years,
we observed a tendency for a lower intensity of CD14
expression in monocytes (p = 0.064), and a higher per-
centage of proinflammatory (CD16+) monocytes in the
first group (median values of 13.2% and 5.9%, respect-
ively; p = 0.035). The other parameters analyzed did not
show statistically significant differences between the
“youngest” and “oldest” individuals, neither between
males and females (p > 0.05).
Circulating immature cells
Immature CD34+ cells represented 0.15 ± 0.28% of the
WBC in the PB from LR-MDS patients (median value of
0.05%, ranging from 0.01 to 1.05%), as compared to 0.03
± 0.01% (median value of 0.03%, ranging from 0.01 to
Table 4 Type and frequency of immunophenotypic aberrancies detected in PB neutrophils from LR-MDS patients versus normal
individuals (controls)
LR-MDS
(n = 14)
Controls
(n = 14)
Decreased Increased Decreased Increased
Abnormal light scatter characteristics
FSC 10 (71%) 1 (7%) 0 (0%) 0 (0%)
SSC 8 (57%) 0 (0%) 0 (0%) 1 (7%)
Abnormal expression of cell surface markers
CD10 9 (64%) 1 (7%) 0 (0%) 0 (0%)
CD11b 10 (71%) 1 (7%) 0 (0%) 1 (7%)
CD11c 10 (71%) 0 (0%) 0 (0%) 0 (0%)
CD13 4 (29%) 1 (7%) 0 (0%) 0 (0%)
CD15 0 (0%) 0 (0%) 1 (7%) 1 (7%)
CD16 6 (43%) 0 (0%) 0 (0%) 0 (0%)
CD45 2 (14%) 1 (7%) 1 (7%) 0 (0%)
Number of individuals with abnormal parameters
No abnormal parameters 1 (7%) 10 (71%) 12 (86%) 11 (79%)
One abnormal parameter 0 (0%) 3 (21%) 2 (14%) 3 (21%)
Two abnormal parameters 2 (14%) 1 (7%) 0 (0%) 0 (0%)
Three abnormal parameters 1 (7%) 0 (0%) 0 (0%) 0 (0%)
Four abnormal parameters 3 (21%) 0 (0%) 0 (0%) 0 (0%)
Five abnormal parameters 4 (29%) 0 (0%) 0 (0%) 0 (0%)
Six abnormal parameters 2 (14%) 0 (0%) 0 (0%) 0 (0%)
Seven abnormal parameters 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Eight abnormal parameters 1 (7%) 0 (0%) 0 (0%) 0 (0%)
Nine abnormal parameters 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB peripheral blood
Results are expressed as absolute and (relative) frequencies
Percentages were approximated to the closest full unit
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and FSC, they were CD45+low, CD34+, CD13+, CD117
−/+, HLA-DR+, and they virtually fail to express all the
other molecules analyzed (CD10, CD11b, CD11c, CD15
and CD16) (data not shown).
Patients with MDS also had increased numbers of cir-
culating immature granulocytes (promyelocytes, myelo-
cytes and metamyelocytes) (1.17 ± 2.03%, with a median
value of 0.36%, ranging from 0.06 to 7.72%), as com-
pared to controls (0.11 ± 0.06%; median value of 0.11%,
ranging from 0.02 to 0.21%). These cells were SSChigh,
FSChigh, CD45+low, CD15+ and CD64+, and they had
variable and low CD11b and CD16 expression, being
negative for the remaining molecules tested (CD10,
CD11c, CD13, CD34, CD56, CD117, HLA-DR) (data not
shown).
Differences between patients and controls reached
statistical significance for circulating immature granu-
locytes (p < 0.001), but not for immature CD34+ cells
(p = 0.056).Immunophenotypic scores
As mentioned above, we defined two FCM-based scor-
ings systems (type 1 and 2) to evaluate dysplasia in neu-
trophils and monocytes, and, for each scoring system, a
total myeloid score was calculated. The results obtained
are summarized in Tables 6 and 7, respectively.
Immunophenotypic scoring schema 1
Neutrophil score type 1
The mean neutrophil score type 1 obtained in LR-MDS
patients was of 4 ± 2, ranging from “0” to 8 (total score
rank = 59), while all controls had a score of 1 or lower
(total score rank = 1), with only 1 case having a score =
1, corresponding to a normal individual whose neutro-
phils had dimmer CD45 expression (Table 6). According
to this score, four groups of MDS patients were identi-
fied: score of “0”, no neutrophil dysplasia (n = 1, corre-
sponding to the patient with a normal neutrophil
immunophenotype mentioned above); score of 1, pos-
sible neutrophil dysplasia (n = 0); score of between 2 and
Fig. 4 FSC, SSC and surface antigen expression in PB monocytes from patients with LR-MDS and healthy individuals (controls). Results as expressed
as arbitrary units of fluorescence intensity. Lower whiskers are 1.5 times the Inter-Quartile Range below the lower quartile, or the minimum value,
whichever is closest to the middle. Upper whiskers are calculated using the same approach. Outliers are displayed. Abbreviations: FSC, forward scatter;
LR-MDS, lower risk myelodysplastic syndromes; MFI, median fluorescence intensity; PB, peripheral blood; SSC, side scatter
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4 and 6, moderate neutrophil dysplasia (n = 9; 64%); and
score over 6, severe neutrophil dysplasia (n = 1; 7%).
Thus, assuming a cut-off of > 1 points we correctly
classified 13 out of 14 LR-MDS patients and 14 out of
14 controls, given a sensitivity of 93% and a specificity of
100% for the diagnosis of MDS.
Monocyte score type 1
The monocytic score type 1 obtained in LR-MDS pa-
tients ranged from 0 to 2 (median 1; mean ± SD of 1 ± 1),
whereas the score observed in controls ranged from 0 to 1
(Table 6). The total score rank for these groups was of 15and 2, respectively. Using this score, four groups of
MDS patients were identified: score of “0”, no
monocyte dysplasia (n = 2; 14%); score of 1, possible
monocyte dysplasia (n = 8; 57%); and score of 2,
monocyte dysplasia (n = 4; 29%). Comparatively, 12
out of 14 controls (86%) had a score of “0”, and the
remaining 2 cases had a score of 1, due to moderate
decrease in the fraction of CD14+CD16+ monocytes
(4.9% and 4.1% of total monocytes, respectively). Con-
sequently, assuming a cut-off of ≥1 points we correctly
categorized 12 out of 14 LR-MDS patients and 12 out of
14 controls, given a sensitivity and a specificity of 86%
for the diagnosis of MDS.
Fig. 5 Bivariate CD16/CD14 and CD56/CD14 dot plots illustrating the depletion of non-classical (intermediate CD14+highCD16+ plus proinflammatory
CD14+lowCD16+) monocytes (upper row) and the aberrant CD56 expression in the PB classical CD14+highCD16− monocytes (lower row) from two
patients with LR-MDS, as compared to a normal individual (control). Light blue dots, classical CD14+highCD16− monocytes; dark blue dots, non-classical
(intermediate CD14+highCD16+ plus proinflammatory CD14+lowCD16+) monocytes; light gray dots, lymphocytes and eosinophils; dark gray dots,
neutrophils. Abbreviations: FSC, forward scatter; LR-MDS, lower risk myelodysplastic syndromes; PB, peripheral blood; SSC, side scatter
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Considering the total myeloid score type 1, obtained by
the sum of the correspondent neutrophil and monocytic
scores, we found a score of 5 ± 2 for LR-MDS (median
of 6, ranging from 0 to 8), while all controls had a scoreTable 5 Immunophenotypic alterations detected in PB monocytes f
Increased CD56 expression in monocytes
CD14+CD56+ cells (% total CD14+ monocytes) (*)
Increased percentages of CD14+ 56+ cells (> 18.0% total CD14+ monocyte
Severity
Mild: CD56+ cells]18%–23%]
Moderate: CD56+ cells [23%–28%]
Severe: CD56+ cells]28%–100%]
Decreased CD16 expression in monocytes
CD14+CD16+ cells (% total CD14+ monocytes) (**)
Decreased percentages of CD14+CD16+ cells (< 5.0% of total CD14+ mon
Severity
Mild: CD16+ cells [2.5%–5.0%]
Moderate: CD16+ cells [1.25–2.5%]
Severe: CD16+ cells [0.00–1.25%]
Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB peripheral blood
Results are expressed as absolute and (relative) frequencies or as median (range) va
Percentages were approximated to the closest full unit
Mann-Whitney U test, LR-MDS patients versus controls: (*) P = 0.026; (**) P < 0.001of 1 or under (Table 6). According to this score, four
groups of MDS patients were identified: score of “0” (no
myelodysplasia) (n = 1; 7%, corresponding to the patient
mentioned above); score of 1 (possible myelodysplasia)
(n = 0); score of between 2 and 4 (n = 3; 21%) (mildrom LR-MDS patients versus normal individuals (controls)
LR-MDS
(n = 14)
Controls
(n = 14)
15 (0–99) 7 (0–15)
s) 6 (43%) 0 (0%)
1 (7%) 0 (0%)
1 (7%) 0 (0%)
4 (29%) 0 (0%)
3 (0–8) 12 (4–28)
ocytes) 9 (64%) 2 (14%)
2 (14%) 2 (14%)
1 (7%) 0 (0%)
6 (43%) 0 (0%)
lues
Table 6 Neutrophil and monocyte immunophenotypic scores,
and total myeloid score for myelodysplasia in the PB from
LR-MDS patients versus normal individuals (controls), taking in
account the number of phenotypic abnormalities found in
each case
LR-MDS
(n = 14)
Controls
(n = 14)
Neutrophil immunophenotypic score 1 (0–8)
Score 5 (0–8) 0 (0–1)
Score rank (Σ) 59 1
Score classes
0 (no dysplasia) 1 (7%) 13 (93%)
1 (possible dysplasia) 0 (0%) 1 (7%)
2–3 (mild dysplasia) 3 (21%) 0 (0%)
4–6 (moderate dysplasia) 9 (64%) 0 (0%)
7–8 (severe dysplasia) 1 (7%) 0 (0%)
Monocyte immunophenotypic score 1 (0–2)
Score 1 (0–2) 0 (0–1)
Score rank (Σ) 15 2
Score classes
0 (no dysplasia) 2 (14%) 12 (86%)
1 (possible dysplasia) 8 (57%) 2 (14%)
2 (dysplasia) 4 (29%) 0 (0%)
Myeloid immunophenotypic score 1 (0–10)
Score 6 (0–8) 0 (0–1)
Score rank (Σ) 74 3
Score classes
0 (no dysplasia) 1 (7%) 11 (79%)
1 (possible dysplasia) 0 (0%) 3 (21%)
2–4 (mild dysplasia) 3 (21%) 0 (0%)
5–7 (moderate dysplasia) 7 (50%) 0 (0%)
8–10 (severe dysplasia) 3 (21%) 0 (0%)
Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB
peripheral blood
Results are expressed as absolute and (relative) frequencies or as median
(range) values
Percentages were approximated to the closest full unit
Neutrophil score: The following parameters were considered: FSC, SSC,
CD10, CD11b, CD11c, CD13, CD16, and CD45. Each abnormally low
parameter (< mean – 2D of the values observed in controls) was scored
with 1 point. Values within the mean ± SD or above the mean + 2SD were
scored with “0”
Monocyte score: The following parameters were considered: % of
CD16+ monocytes and % of CD56+ monocytes. These parameters
were scored as follows: CD14 + CD56+ monocytes: ≤18% (0 points);
> 18% (1 point); CD14 + CD16+ monocytes: ≥5% (0 points); < 5%
(1 point)
Myeloid score: obtained by adding up the neutrophil and the monocytic score
achieved for each patient
The following score rankings were obtained for each of the parameters
analyzed: Patients: FSC = 10; CD11b = 10; CD11c = 10; CD10 = 9; SSC = 8;
CD13 = 4; CD15 = 0; CD16 = 6; CD45 = 2. Controls: CD15 = 1; CD45 = 1;
other parameters = 0
Table 7 Neutrophil and monocyte immunophenotypic scores,
and total myeloid score for myelodysplasia in the PB from
LR-MDS patients versus normal individuals (controls), taking
in account the number and the severity of the phenotypic
abnormalities found in each case
LR-MDS
(n = 14)
Controls
(n = 14)
Neutrophil immunophenotypic score 2 (0–8)
Score 2 (0–3) 0 (0–0)
Score rank (Σ) 28 0
Score classes
0 (no dysplasia) 1 (7%) 14 (100%)
1 (possible dysplasia) 2 (14%) 0 (0%)
2–3 (mild dysplasia) 11 (79%) 0 (0%)
4–6 (moderate dysplasia) 0 (0%) 0 (0%)
7–8 (severe dysplasia) 0 (0%) 0 (0%)
Monocyte immunophenotypic score 2 (0–2)
Score 1 (0–2) 0 (0–0)
Score rank (Σ) 12 1
Score classes
0 (no dysplasia) 5 (36%) 14 (100%)
1 (probable dysplasia) 6 (43%) 0 (0%)
2 (dysplasia) 3 (21%) 0 (0%)
Myeloid immunophenotypic score 2 (0–10)
Score 3 (0–5) 0 (0–1)
Score rank (Σ) 39 1
Score classes
0 (no dysplasia) 1 (7%) 14 (0%)
1 (possible dysplasia) 1 (7%) 0 (0%)
2–4 (mild dysplasia) 11 (79%) 0 (0%)
5–7 (moderate dysplasia) 1 (7%) 0 (0%)
8–10 (severe dysplasia) 0 (0%) 0 (0%)
Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB
peripheral blood
Results are expressed as absolute and (relative) frequencies or as median
(range) values
Percentages were approximated to the closest full unit
Neutrophil score: The following parameters were considered: FSC, SSC, CD10,
CD11b, CD11c, CD13, CD16, and CD45. Values within the mean ± SD or above
the mean + 2SD were scored with “0”. Abnormally low parameter (< mean-2D
of the values observed in controls) were scored as follows: (< mean-2D: 0.25
points; < mean-3SD: 0.5 points; < mean-3SD: 1 point
Monocyte score: The following parameters were considered: % of CD16+
monocytes and % of CD56+ monocytes. These parameters were scored as
follows: CD14 + CD56+ monocytes: ≤18% (0 points); >mean + 2SD (18%): 0.25
points; > mean + 3SD (23%): 0.5 points; > mean + 4SD (28%): 1 point. CD14 +
CD16+ monocytes: ≥5%: 0 points; CD14 + CD16+ monocytes < 5%: 0.25 point;
CD14 + CD16+ monocytes: < 2.5%: 0.5 points; CD14 + CD16+ monocytes: <
1.25%: 1 point
Myeloid score: obtained by adding up the neutrophil score 1 and the
monocytic score achieved for each patient
The following score rankings were obtained for each of the parameters
analyzed: Patients: FSC = 6.5; CD11c = 5.5; CD11b = 5.0; SSC = 4.5; CD10 = 2.5;
CD16 = 2; CD13 = 1.0; CD15 = 0.0; CD45 = 0.5. Controls: CD15 = 0.25; CD45 = 0.25;
other parameters = 0
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lodysplasia) (n = 7; 50%); and score over 8 (severe myelo-
dysplasia) (n = 3; 21%). In contrast, in the control group,
most of the individuals had a score of “0”, with only 3
(21%) having a score of 1. Therefore, assuming a cut-off
of ≥2 points we were able to correctly classify 13 out of
14 LR-MDS patients and 14 out of 14 controls, given a
sensitivity of 93% and a specificity of 100% for the diag-
nosis of MDS.
Immunophenotypic scoring schema 2
Neutrophil score type 2
The mean neutrophil score type 2 obtained in LR-MDS
patients was of 2 ± 1, ranging from 0 to 3 (total score
rank = 28), while all controls had a score of “0” (Table 7).
According to this score, four groups of MDS patients
were identified: score of “0”, no dysplasia (n = 1; 7%); ii)
score of 1 (n = 2; 14%); score between 2 and 3 (n = 1;
7%); score between 4 and 6 (n = 0); and score over 6
(n = 0). Thus, similarly to that observed with the neutro-
phil scoring system type 1, assuming a cut-off of > 1 points
we were able to correctly classify 13 out of 14 LR-MDS
patients and 14 out of 14 controls (sensitivity of 93%
and specificity of 100% for the diagnosis of MDS).
Monocyte score type 2
The mean monocyte score type 2 obtained in LR-MDS
patients was of 1 ± 1, ranging from 0 to 2 (total score
rank = 12), whereas the score observed in controls was
of “0” in all cases (Table 7). According this score, four
groups of MDS patients were identified: score of “0”
(n = 5; 36%); score of 1 (n = 6; 43%); and score of 2
(n = 3; 21%). Comparatively, all controls had a score
of “0”. Consequently, assuming a cut-off of ≥1 point
we were able to correctly classify 9 out of 14 LR-MDS
patients and all controls, given a sensitivity and a
specificity of 64% for the diagnosis of MDS.
Myeloid score type 2
Considering the total myeloid score type 2, i.e. the sum
of the neutrophil and monocytic scores type 2, we ob-
tained a score of 3 ± 1 for LR-MDS (median of 3, ran-
ging from 0 to 8, total score rank = 39), while all
controls had a score of 1 or under (Table 7).
As a result, the scoring schemas type 2 apparently do
not offer advantages for the diagnosis of myelodysplasia,
as compared to the scoring schemas type 1, which are
more easily to calculate.
MDS thermometers
The immunophenotypic scoring schemas type 1 were
used to conceive the MDS Thermometer tool, aimed for
the screening of MDS in PB samples in clinical practice,
which can be deployed on two thermometers, forneutrophils and monocytes, respectively (Fig. 6). The
neutrophil thermometer is based on the neutrophil score
system type 1, i.e., the number of cell surface markers
abnormally low expressed in neutrophils, among 8 pa-
rameters considered (FSC, SSC, CD10, CD11b, CD11c,
CD13, CD16 and CD45). The monocyte thermometer is
based on the monocyte scoring system type 1, i.e., in-
creased fraction of CD56+ cells (aberrant CD56 expres-
sion) and decreased fraction of CD16+ cells (depletion of
proinflammatory monocytes) among total monocytes.
The myeloid thermometer was obtained by the sum of
the neutrophil and the monocyte type 1 scores.
Discussion
Progresses made in the last years concerning the assess-
ment of MDS by FCM have led to consensus recom-
mendations for the integration of FCM data in the
diagnostic work-up of MDS [21]. However, establishing
the diagnosis still requires BM aspirate and biopsy,
which are invasive procedures and not always conclu-
sive, especially in LR-MDS.
Given the frequency of MDS patients with mild cytope-
nias that would not demand therapeutic intervention, due
the fact that most MDS patients are not eligible for inten-
sive treatment schedules, and taking into account the easy
access to PB samples, it would be desirable to have a PB
assay to help guide the need for invasive BM evaluation.
Nonetheless, immunophenotypic studies in the PB from
patients with MDS are surprisingly scarce. Using the
PubMed and applying the key words “flow cytometry”,
“myelodysplastic syndromes”, and “peripheral blood”, we
found only five studies performed in the PB [27–31].
Cherian et al. (2005) observed that neutrophils from
MDS patients had lower SSC and higher expression of
CD66 and CD11a than did controls; in some cases, PB
neutrophils also displayed abnormal CD116 and CD10
expression [27, 28]. Using these markers, they proposed
a score that allowed to distinguish MDS patients from
normal controls with a sensitivity of 73% and a specifi-
city of 90% [28].
Some years later (2012), using 3-color FCM, Rashidi
et al. observed that CD10 expression on PB neutrophils
was significantly decreased in patients with HR-MDS
and CMML compared to both non-MDS patients with
pancytopenia and to LR-MDS patients [30]. In contrast,
they found no significant differences in CD11b, CD13,
CD14, CD16, CD33, CD56, and CD64 expression in
neutrophils and monocytes from the mentioned groups
of patients.
More recently (2013), Meyerson et al. realized that low
CD177 expression was frequent in PB and BM neutrophils
from patients with clonal myeloid disorders; these findings
were most pronounced in MDS, with 52% of cases con-
taining less than 40% of CD177+ neutrophils [31].
Fig. 6 MDS Thermometers. The neutrophil thermometer is based on the neutrophil score system type 1, i.e., the number of cell surface markers
abnormally low expressed in PB neutrophils, among 8 parameters considered (FSC, SSC, CD10, CD11b, CD11c, CD13, CD16 and CD45). The monocyte
thermometer is based on the monocyte scoring system type 1, i.e., increased fraction of CD56+ cells (aberrant CD56 expression) and decreased
fraction of CD16+ cells (depletion of proinflammatory monocytes) among total PB monocytes. The myeloid thermometer was obtained by the sum of
the neutrophil and the monocyte type 1 scores. Abbreviations: FSC, forward scatter; PB, peripheral blood; SSC, side scatter
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consisting of abnormal light scatter characteristics, over
or under expression of platelet glycoproteins and asyn-
chronous CD34 expression were also described in pa-
tients with MDS [29].
Our pilot study revealed, for the first time, that PB neu-
trophils from LR-MDS not only frequently have decreased
FSC and/or SSC, but also commonly display abnormally
low levels of CD11b, CD11c, CD10, CD16, CD13 and
CD45 expression, as compared to normal neutrophils.
The fact that 93% of these patients had abnormally low
levels of 2 or more (out of 9) cell surface molecules on
neutrophils, as compared to only 29% having abnormal
morphology, clearly indicates that FCM is more sensitive
for the detection of myelodysplasia in the PB than cyto-
morphology. In addition, we observed a marked deficiency
in proinflammatory CD16+ monocytes and a high fre-
quency of CD56 expression in circulating monocytes from
patients with LR-MDS, irrespectively of the monocyte
counts.
Human PB monocytes have been divided into distinct
subsets, referred to as classical (CD14+CD16−) and non-
classical (CD14+CD16+) monocytes; in between, there are
“intermediate” monocytes, which are transitional cells –
for review see [45–48]. CD14+CD16+ monocytes, which
were first described in the late 80 [49], account for about10% of total PB monocytes in healthy adults and appear to
be more mature; they express lower levels of CD14 and
higher levels of HLA-DR (CD14+lowCD16+HLA-DR+high)
as compared with classical (CD14+highCD16−HLA-DRlow)
monocytes [50], and they have distinct patterns of cyto-
kines and chemokine receptors. Specifically, CD14+CD16+
monocytes have been shown to efficiently produce tumor
necrosis factor (TNF), while they produce no or less of the
anti-inflammatory cytokine interleukin (IL)-10 [51, 52]. In
opposition to classical monocytes, they lack surface
expression of CC chemokine receptor type 2 (CCR2), the
receptor for monocyte chemotactic protein-1 (MCP-1),
and have higher surface expression of CCR5, the receptor
for macrophage inflammatory protein 1 alpha (MIP-
1alpha) /regulated on activation, normal T cell expressed
and secreted (RANTES) chemokine [53]. Their numbers
are increased in various pathological conditions, such as
HIV infection [54], sepsis [55], inflammatory bowel dis-
eases [56], other inflammatory and autoimmune conditions
[57], and tumors [58, 59], and they have been associated
with acute or chronic inflammation. In addition, the rela-
tive and absolute numbers of the ‘non-classical’ CD14
+CD16+ monocytes increase with the age [60].
Herein we described, for the first time, a depletion of
proinflammatory (CD14+CD16+) monocytes, with conse-
quent increase in the fraction of classical (CD14+CD16−)
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may explain the abnormally low levels of CD11c, CD16
and HLA-DR expression we observed in PB monocytes
from patients with LR-MDS. The reasons for this abnormal
repartition of the PB monocyte subsets observed in pa-
tients with MDS are not clear. Patients included were not
medicated with corticosteroids, which are known to induce
a selective depletion of the CD14+CD16+ monocytes [61].
Also, it cannot be explained by aging, as in healthy individ-
uals, proinflammatory CD14+CD16+ monocytes signifi-
cantly increase with age, as we observed in our control
group. Maybe this is a consequence of a defective mono-
cyte maturation, as already described for CMML [62].
Curiously, Selimoglu-Buet et al. have recently found an
increase in the fraction of classical CD14+CD16− mono-
cytes, in the PB from patients with CMML, as compared
to healthy individuals and to patients with reactive mono-
cytosis [18]. Taking in account that, as stated above, an
opposite abnormal repartition of the mentioned monocyte
subsets, with increased fractions of CD16+ monocytes, has
been described in inflammatory and autoimmune condi-
tions [56, 57], infections [54, 55, 57, 63], and cancer [58,
59], the selective depletion of CD14+CD16+ monocytes
in the PB would probably be important for the differential
diagnosis between MDS and non-MDS cytopenias.
Abnormal CD56 expression in BM monocytes has
already been described in patients with MDS, being
observed with higher frequency in HR-MDS, as com-
pared to LR-MDS [64], and is also a frequent in CMML
[17, 20, 64], although these findings are not completely
understood.
In healthy individuals, around 10% of the monocytes co-
express CD56, with the majority of CD56+ monocytes be-
ing CD14+high [65, 66]. CD56+ monocytes are expanded in
aging individuals as well as in patients with autoimmune
and inflammatory conditions, such as rheumatoid arthritis
and inflammatory bowel diseases [66, 67]. Compared to
CD56− monocytes, CD56+ monocytes spontaneously
produce more reactive oxygen intermediates and, upon
stimulation, they are stronger producers of cytokines, such
as TNF, IL-10 and IL-23 [66]. As so, CD56 expression was
recognized as a signal of monocyte activation and/or
immunosenescence [66]. Considering the simultaneous
decreased fractions of CD14+lowCD16+ and increased frac-
tions of CD14+highCD56+ monocytes observed in MDS
patients, we postulate that blockage of differentiation of
classical (CD14+highCD16−) into proinflammatory (CD14
+lowCD16+) monocytes leads to accumulation of the first
monocyte population in the PB, which becomes senescent
and then acquire CD56 expression.
The phenotypic aberrancies observed in the PB from
patients with LR-MDS are consistent with those that
have been previously described in the BM, and the
2-tubes/8-color panel we proposed for the screening ofmyelodysplasia in the PB would allow to evaluate most
of the aberrant immunophenotypic features that have
been suggested being included in BM studies for the
diagnostic work-up of patients with MDS [13, 21]. The
exceptions are lineage infidelity markers and some
myeloid-associated markers, which are not evaluated
with our protocol. In addition, our FCM panel can also
be used to quantify and characterize the immature
CD34+ cells, both in the PB and BM samples. For the
evaluation of the myeloid and lymphoid compartments
in CD34+ BM cells, CD19 may be used instead of CD15,
as this marker did not prove to be useful for the diagno-
sis of neutrophil dysplasia.
Several FCM scoring schemas have been already pro-
posed for diagnosis and prognosis evaluation in MDS,
most of them based on the immunophenotypic features
of the BM blast cells and on the abnormal immunophe-
notypic patterns found in maturing myeloid cells [10, 12,
68]. However, due to the complexity of BM analysis,
these schemas are difficult to apply in routine clinical
practice. To become clinically applicable, FCM should
be not only sensitive and specific, but also reproducible,
and the results should be easily understood by clinicians.
Therefore, our study fills a gap and refine the accuracy
to detect myelodysplasia in the PB.
The visual analogue scale we propose for the screening
of myelodysplasia in PB samples – the MDS thermom-
eter, is simple, intuitive and easy to apply. It is based on
FCM analysis of 10 parameters, 8 in neutrophils (FSC,
SSC, CD10, CD11b, CD11c, CD16, CD45) and 2 in
monocytes (CD16, CD56), and it allows to distinguish
LR-MDS peripheral blood samples from normal PB sam-
ples with a sensitivity of 100% and a specificity of 93%. It
could be argued that it does not take into account the
severity of the deficiency of each molecule observed in
myelodysplastic cells. However, the alternative scoring
schema that evaluates this aspect but is more difficult to
apply, did not improve the performance of the test;
maybe it can be useful in specific cases. With the neces-
sary adaptations, the concept of the MDS Thermometer
could probably also be applied to the MDS/MPN, such
as CMML, in which monocytic aberrancies are expected
to be more pronounced.
There are some limitations to the current study. First,
the number of cases studied is small and this study
should be considered a pilot study. Secondly, due to the
difficulties in finding blood donors older than 60 years,
we were not able to pair healthy controls and MDS pa-
tients for age, and it could be argued that differences be-
tween groups may be age-related; however, the fact that
no differences were found in the analyzed parameters
when younger and older healthy volunteers were com-
pared, except for a higher fraction of CD16+ monocytes
in the last group, strongly argue against this possibility.
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penias. Finally, attention should be given to the cyt-
ometer setup, calibration and stability, and each center
should establish its own normal reference values, on the
basis of the mAbs and experimental conditions used.
Conclusions
Our pilot study reveals an altered neutrophil immuno-
phenotype, often accompanied by an abnormal mono-
cyte immunophenotype, in the PB from nearly all LR-
MDS cases, and suggests that assessment of abnormal
antigen expression in PB mature myeloid cells may help
to identify patients with LR-MDS. Once translated into a
straightforward FCM-based score and converted into a
visual analogue scale – MDS thermometer –, these find-
ings can be easily applied in clinical practice. However,
due to the low number of cases analyzed, further studies
with larger series of patients are needed to confirm our
preliminary observations. Furthermore, it would be in-
teresting to evaluate HR-MDS patients, as well as
CMML and other MDS/MPN. Additional studies are
also required in order to evaluate the specificity of such
alterations for the diagnosis MDS, by testing other
pathological conditions associated with cytopenias.
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